This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
NME1 · Western blot design guide
NME1 Western Blot Planning Guide
Plan a NME1 Western blot around the catalog-observed 17.1 kDa band, image-backed PA1829 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
NME1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 17.1 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 15% | |
| Positive control | Breast | |
| Negative control | Heart muscle |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 17.1 kDa |
| ⓘ | Localization | Cytoplasm / Nucleus |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated NME1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Breast |
| Gel % | 15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, short transfer |
| Membrane | 0.2 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA1829 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected NME1 Western Blot Band Size?
Use the product-observed 17.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 17.1 kDa | Matches the authoritative product WB observation. |
| 17.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected NME1 appearancePlan around 17.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 17.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 17.1 kDa from UniProt P15531; retain as context. |
| Gel selection | 15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA1829. |
| Situation | Likely cause | Next action |
|---|---|---|
| 17.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing NME1 band
PA1829 · NME1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for NME1 Western blot
🧪Use Breast as the first positive-control candidate and Heart muscle as the HPA Not detected negative candidate.
Positive control: Breast (High)
Negative control: Heart muscle (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for NME1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
| Lymph node | Reported tissue cells | High | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced NME1 Western Blot Tips
Deeper troubleshooting and optimisation questions for NME1, answered from its protein features.
Which band should guide the blot?
Use 17.1 kDa, the observation attached to the authoritative PA1829 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 17.1 kDa expectation.
Which positive control should I start with?
Start with Breast, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Heart muscle as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for NME1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA1829 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC8212152, PMC8195739, PMC6115381.
Boster reagents
NME1 Western Blot Reagents
Human/Mouse/Rat-reactive NME1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-NM23A/NME1 Antibody Picoband®
Cat # PA1829
Real WB data
Anti-NM23A/NME1 Antibody Picoband®
Cat # RP1090
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P15531
- Human Protein Atlas — NME1
- PA1829 product record
- PMC8212152 — Regulation of metastasis suppressor NME1 by a key metabolic cofactor coenzyme A.
- PMC8195739 — Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance.
- PMC6115381 — Foot-and-mouth disease virus induces lysosomal degradation of NME1 to impair p53-regulated interferon-inducible antiviral genes expression.